SCHEMBL12259147

SCHEMBL12259147

Cc1ccc(Nc2nc(-c3ccc(NC(=O)c4ccccc4)cc3)cs2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.86
KMT2A Q03164 6/20 0.86
NFKB1 P19838 1/20 0.70
NFKB2 Q00653 1/20 0.70
RELA Q04206 1/20 0.70
MAPT P10636 11/20 0.70
ALDH1A1 P00352 2/20 0.70
HPGD P15428 1/20 0.70
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
GAA P10253 4/20 0.68
NPSR1 Q6W5P4 2/20 0.68
KDM4E B2RXH2 5/20 0.67
MAPK1 P28482 2/20 0.67
LMNA P02545 1/20 0.67
HTT P42858 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
POLB P06746 1/20 0.66
ALOX5 P09917 1/20 0.64
AMY1A P0DUB6 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585750 0.89 MEN1 (0.88) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL2753872 0.88 LMNA (0.77) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL28575125 0.84 MAPT (0.72) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL10072694 0.84 ALOX5 (0.74) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL1819906 0.84 RAB9A (0.78) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL233522 0.83 SCD (0.78) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL27885076 0.83 NFKB1 (1.00) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL20379817 0.82 CSNK2A1 (0.75) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL12316832 0.82 MEN1 (0.79) MEN1KMT2ANFKB1NFKB2RELA
SCHEMBL17320209 0.82 ALOX5 (0.85) MEN1KMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20160171150-A1 Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides DANA-FARBER CANCER INSTITUTE, INC. 2016-06-16 US disclosed
US-20160171150-A1 Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides DANA-FARBER CANCER INSTITUTE, INC. 2016-06-16 US disclosed
US-20110218155-A1 CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-09-08 US disclosed
US-20110218155-A1 CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 MEN1 3416/4885KMT2A 3471/4885NFKB1 487/4885
US-20110218155-A1 CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES BAX, BCL2, BCL2L1 MEN1 3300/4885KMT2A 3136/4885NFKB1 705/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA MEN1 2434/4885KMT2A 2501/4885NFKB1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.